AR045235A1 - Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen. - Google Patents

Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.

Info

Publication number
AR045235A1
AR045235A1 ARP040102851A ARP040102851A AR045235A1 AR 045235 A1 AR045235 A1 AR 045235A1 AR P040102851 A ARP040102851 A AR P040102851A AR P040102851 A ARP040102851 A AR P040102851A AR 045235 A1 AR045235 A1 AR 045235A1
Authority
AR
Argentina
Prior art keywords
group
hydroxyalkyl starch
reacting
functional group
compound
Prior art date
Application number
ARP040102851A
Other languages
English (en)
Original Assignee
Fresenius Kabi De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31995520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045235(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02020425A external-priority patent/EP1400533A1/en
Application filed by Fresenius Kabi De Gmbh filed Critical Fresenius Kabi De Gmbh
Publication of AR045235A1 publication Critical patent/AR045235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C08B31/10—Alkyl or cycloalkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C08B31/006—Crosslinking of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/08—Ethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C08B31/185—Derivatives of oxidised starch, e.g. crosslinked oxidised starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a un método para producir un derivado de almidón de hidroxialquilo, dicho derivado de almidón de hidroxialquilo que tiene una estructura de acuerdo con la fórmula (1), que comprende hacer reaccionar: el almidón de hidroxialquilo de la fórmula (1) en su extremo reductor opcionalmente oxidado; o un derivado del almidón de hidroxialquilo que se puede obtener haciendo reaccionar el almidón de hidroxialquilo de la fórmula (1) en su extremo reductor opcionalmente oxidado con un compuesto (D), dicho compuesto (D) que comprende: por lo menos un grupo funcional Z1 capaz de hacerse reaccionar con el extremo reductor opcionalmente oxidado del almidón de hidroxialquilo; y por lo menos, un grupo funcional W, con un compuesto (L) que comprende: por lo menos un grupo funcional Z1 capaz de reaccionar con dicho almidón de hidroxialquilo, o por lo menos un grupo funcional Z2 capaz de hacerse reaccionar con el grupo funcional W comprendido en dicho derivado; y por lo menos un grupo funcional X capaz de hacerse reaccionar con un grupo funcional Y de un compuesto adicional (M), en el cual dicho grupo funcional Y es seleccionado a partir del grupo que consiste en un grupo aldehído, un grupo ceto, un grupo hemiacetal, un grupo acetal, y un grupo tio. La presente también se refiere a los derivados de almidón de hidroxialquilo como tal, y a una composición farmacéutica que comprende dichos derivados de almidón de hidroxialquilo.
ARP040102851A 2002-09-11 2004-08-09 Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen. AR045235A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40978102P 2002-09-11 2002-09-11
EP02020425A EP1400533A1 (en) 2002-09-11 2002-09-11 HASylated polypeptides, especially HASylated erythropoietin
PCT/EP2003/008858 WO2004024761A1 (en) 2002-09-11 2003-08-08 Hasylated polypeptides, especially hasylated erythropoietin
PCT/EP2003/008829 WO2004024776A1 (en) 2002-09-11 2003-08-08 Method of producing hydroxyalkyl starch derivatives

Publications (1)

Publication Number Publication Date
AR045235A1 true AR045235A1 (es) 2005-10-19

Family

ID=31995520

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP030103141A AR041097A1 (es) 2002-09-11 2003-08-29 Derivados de polipeptidos con hidroxilalquilalmidon especialmente derivados de eritropoyetina con hidroxilalquilalmidon
ARP040102851A AR045235A1 (es) 2002-09-11 2004-08-09 Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.
ARP040102850A AR045234A1 (es) 2002-09-11 2004-08-09 Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030103141A AR041097A1 (es) 2002-09-11 2003-08-29 Derivados de polipeptidos con hidroxilalquilalmidon especialmente derivados de eritropoyetina con hidroxilalquilalmidon

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP040102850A AR045234A1 (es) 2002-09-11 2004-08-09 Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.

Country Status (24)

Country Link
US (5) US20050238723A1 (es)
EP (9) EP1398328B1 (es)
JP (4) JP2006516534A (es)
KR (3) KR101045401B1 (es)
CN (2) CN1681844A (es)
AR (3) AR041097A1 (es)
AT (3) ATE323723T1 (es)
AU (6) AU2003260393B2 (es)
BR (3) BR0314227A (es)
CA (2) CA2495242A1 (es)
CY (1) CY1109813T1 (es)
DE (7) DE60304640T2 (es)
DK (3) DK1398328T3 (es)
ES (4) ES2213506T3 (es)
IL (5) IL166506A0 (es)
MX (4) MXPA05002594A (es)
NO (2) NO20051427L (es)
PL (3) PL375037A1 (es)
PT (3) PT1398328E (es)
RU (3) RU2329274C2 (es)
SI (2) SI1398327T1 (es)
TW (1) TW200418875A (es)
WO (3) WO2004024776A1 (es)
ZA (1) ZA200600651B (es)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
BR0314227A (pt) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
EP1400533A1 (en) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
DE10256558A1 (de) * 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
PL1660134T3 (pl) * 2003-08-08 2011-05-31 Fresenius Kabi Deutschland Gmbh Koniugaty hydroksyalkiloskrobi i G-CSF
MXPA06001358A (es) * 2003-08-08 2006-05-15 Fresenius Kabi Gmbh Conjugados de hidroxialquil almidon y g-csf.
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
BRPI0412671A (pt) * 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
WO2005092369A2 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyethyl starch and erythropoietin
JP5191729B2 (ja) * 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
ES2390885T3 (es) * 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
WO2006094826A2 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Method for coupling enzymatically activated glycoconjugates to a hydroxyalkyl starch
CN101137396A (zh) * 2005-03-11 2008-03-05 弗雷泽纽斯卡比德国有限公司 由无活性初始材料制备生物活性糖蛋白
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
CN101528263B (zh) 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
US8299015B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
PT2101821E (pt) * 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN104888264B (zh) 2008-01-14 2018-01-09 北京环球利康科技有限公司 生物相容性止血、防粘连、促愈合、外科封闭的变性淀粉材料
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US8790701B2 (en) * 2008-04-28 2014-07-29 Surmodics, Inc. Poly-α(1→4)glucopyranose-based matrices with hydrazide crosslinking
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP6018753B2 (ja) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
BRPI0920896B8 (pt) 2008-12-06 2021-05-25 Braun Melsungen Ag composto de fórmula geral (i) (t-z)n-p (i), formulação farmacêutica e processo para preparar um composto de fórmula geral (i)
EP2400979B1 (en) 2009-02-26 2015-05-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
CN102365099A (zh) * 2009-03-31 2012-02-29 B·布朗·梅尔松根有限公司 胺化多糖粘合制品
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) * 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011050333A1 (en) 2009-10-23 2011-04-28 Amgen Inc. Vial adapter and system
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
SG186094A1 (en) 2010-06-07 2013-01-30 Amgen Inc Drug delivery device
WO2012004007A1 (en) * 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
US20140088298A9 (en) * 2010-07-09 2014-03-27 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
WO2012004004A1 (en) 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Nitric oxide delivering hydroxyalkyl starch derivatives
EP2590678A1 (en) * 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
HUE042822T2 (hu) 2011-04-20 2019-07-29 Amgen Inc Automata befecskendezõ szerkezet
JP2014520094A (ja) 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
US20150044714A1 (en) * 2011-06-07 2015-02-12 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine sPLA2 MONITORING STRIP
US20140371292A1 (en) 2011-08-10 2014-12-18 Ludwig-Maximilians-Universitat Munchen Method for the controlled intracellular delivery of nucleic acids
PL3045187T3 (pl) 2011-10-14 2019-09-30 Amgen Inc. Wstrzykiwacz i sposób montażu
WO2013113503A1 (en) 2012-01-31 2013-08-08 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and an oligonucleotide
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
ES2860954T3 (es) 2012-11-21 2021-10-05 Amgen Inc Dispositivo de administración de fármacos
WO2014084110A1 (ja) * 2012-11-30 2014-06-05 株式会社糖鎖工学研究所 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
US10646664B2 (en) 2013-03-15 2020-05-12 Amgen Inc. Body contour adaptable autoinjector device
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
AU2014234270A1 (en) * 2013-03-20 2015-10-08 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives as reactants for coupling to thiol groups
EP2976365A1 (en) * 2013-03-20 2016-01-27 Fresenius Kabi Deutschland GmbH Process for the preparation of thiol functionalized hydroxyalkyl starch derivatives
CA2907371A1 (en) * 2013-03-20 2014-09-25 Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives as reactants for coupling to thiol groups
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
WO2015046183A1 (ja) 2013-09-24 2015-04-02 味の素株式会社 糖アミノ酸およびその用途
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
MX2016010294A (es) * 2014-02-10 2016-10-17 Honeywell Int Inc Diseño de reactor para la fluoracion en fase liquida.
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
CN111840696B (zh) 2014-06-03 2022-12-20 安姆根有限公司 可控制药物递送系统和使用方法
CN104072608A (zh) * 2014-06-23 2014-10-01 山东齐都药业有限公司 含羧基羟乙基淀粉衍生物修饰的牛血清白蛋白偶联物及其制备方法
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
EP3206739B1 (en) 2014-10-14 2021-12-01 Amgen Inc. Drug injection device with visual and audio indicators
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び／または戻りが真空によって支援された薬物送達装置
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
SG11201804666QA (en) 2015-12-03 2018-06-28 Baxalta Inc Factor viii with extended half-life and reduced ligand-binding properties
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3458085B1 (en) 2016-05-20 2022-12-07 Octapharma AG Glycosylated vwf fusion proteins with improved pharmacokinetics
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
EP3592403B1 (en) 2017-03-06 2025-08-20 Amgen Inc. Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
ES3023742T3 (en) 2017-03-28 2025-06-03 Amgen Inc Plunger rod and syringe assembly system
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en) 2017-07-14 2023-11-01 Amgen Inc Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
ES2971450T3 (es) 2017-10-06 2024-06-05 Amgen Inc Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en) 2017-11-03 2024-12-01 Amgen Inc Systems and approaches for sterilizing a drug delivery device
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
MX2020005066A (es) 2017-11-16 2020-08-20 Amgen Inc Autoinyector con deteccion de detencion y punto final.
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
CN108219019B (zh) * 2018-02-08 2020-03-20 华中科技大学 一种巯基化羟乙基淀粉及其修饰的纳米材料和制备方法
CN108403641B (zh) * 2018-02-08 2020-03-20 华中科技大学 一种载药纳米材料及其制备方法
CN108503718B (zh) * 2018-02-08 2020-03-20 华中科技大学 一种羟烷基淀粉偶联物及其制备方法和应用
US11191806B2 (en) * 2018-05-04 2021-12-07 Boris Farber Polymyxin-based pharmaceutical composition for treating infectious diseases
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
CN111157736A (zh) * 2018-11-08 2020-05-15 中国科学院大连化学物理研究所 一种基于化学酶促的人血清o糖基化鉴定方法
WO2020099513A1 (en) 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
JP2024523779A (ja) 2021-05-21 2024-07-02 アムジェン インコーポレイテッド 薬物容器用の充填レシピを最適化する方法
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
CN116790698B (zh) * 2023-06-21 2024-06-18 南京大学 基于氧化脱羧酶的硫醛合成方法及其应用
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (es)
US3191291A (en) 1959-01-21 1965-06-29 Continental Can Co Art of producing very thin steel and like sheets in wide strips
CH385787A (de) * 1960-10-04 1964-09-15 Hoechst Ag Verfahren zur Herstellung von nassechten Färbungen auf Cellulosetextilmaterialien
GB1385403A (en) 1971-07-14 1975-02-26 Unilever Ltd Process for preparing oxidised carbohydrates
GB1419080A (en) 1972-12-29 1975-12-24 Cheminova As Chemical compounds having juvenile hormone activity
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4125492A (en) * 1974-05-31 1978-11-14 Pedro Cuatrecasas Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) * 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4061736A (en) * 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) * 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
GB1578348A (en) 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
FR2378094A2 (fr) 1977-01-24 1978-08-18 Inst Nat Sante Rech Med Nouveaux reactifs biologiques constitues par des supports solides sur lesquels sont couples des composes organiques comportant un residu glucidique
EP0019403B1 (en) * 1979-05-10 1985-07-31 American Hospital Supply Corporation Hydroxyalkyl-starch drug carrier
DE3029307A1 (de) * 1980-08-01 1982-03-04 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Haemoglobin enthaltendes blutersatzmittel
US4454161A (en) * 1981-02-07 1984-06-12 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for the production of branching enzyme, and a method for improving the qualities of food products therewith
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
SK280623B6 (sk) * 1985-01-03 2000-05-16 Genetics Institute Rekombinantný dna plazmidový vektor, cicavčia bunk
DE3501616A1 (de) 1985-01-17 1986-07-17 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von hydroxylamin-derivaten
US4667016A (en) 1985-06-20 1987-05-19 Kirin-Amgen, Inc. Erythropoietin purification
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5217998A (en) * 1985-07-02 1993-06-08 Biomedical Frontiers, Inc. Composition for the stabilization of deferoxamine to chelate free ions in physiological fluid
US4863964A (en) * 1985-07-02 1989-09-05 Biomedical Frontiers, Inc. Method for the stabilization of deferoxamine to chelate free ions in physiological fluid
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IT1203814B (it) 1986-06-30 1989-02-23 Fidia Farmaceutici Esteri dell'acido alginico
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP2594123B2 (ja) * 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0307827A3 (en) 1987-09-15 1989-12-27 Kuraray Co., Ltd. Novel macromolecular complexes, process for producing same and medicinal use of such complexes
IL84252A (en) 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DK110188D0 (da) 1988-03-02 1988-03-02 Claus Selch Larsen High molecular weight prodrug derivatives of antiinflammatory drugs
FR2630329B1 (fr) * 1988-04-20 1991-07-05 Merieux Inst Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
IT1219942B (it) 1988-05-13 1990-05-24 Fidia Farmaceutici Esteri polisaccaridici
US4900780A (en) * 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
DE3836600A1 (de) 1988-10-27 1990-05-03 Wolff Walsrode Ag Kohlensaeureester von polysacchariden und verfahren zu ihrer herstellung
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US6261800B1 (en) * 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
DE19975071I2 (de) 1989-06-16 2000-02-03 Fresenius Ag Hydroxyethylstaerke als Plasmaexpander Verfahren zu ihrer Herstellung und Verwendung als kolloidales Plasmaersatzmittel
JP2896580B2 (ja) 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
JP2975632B2 (ja) 1990-03-30 1999-11-10 生化学工業株式会社 グリコサミノグリカン修飾プロテイン
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
DK130991D0 (da) 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
DE4130807A1 (de) 1991-09-17 1993-03-18 Wolff Walsrode Ag Verfahren zur herstellung von polysaccharidcarbonaten
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
WO1994005332A2 (en) * 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
GB2270920B (en) 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
CA2110543A1 (en) 1992-12-09 1994-06-10 David E. Wright Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
FI935485L (fi) 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
EP0601417A3 (de) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
DK0646130T3 (da) 1993-03-16 1997-06-02 Hemosol Inc Selektiv tværbinding af hæmoglobiner ved hjælp af oxiderede, ringåbnede saccharider
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
JPH07188291A (ja) 1993-12-27 1995-07-25 Hayashibara Biochem Lab Inc 蛋白質とその製造方法並びに用途
US5876980A (en) * 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
US5723589A (en) * 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
US5696152A (en) 1996-05-07 1997-12-09 Wisconsin Alumni Research Foundation Taxol composition for use as organ preservation and cardioplegic agents
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6011008A (en) 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
US5952347A (en) 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
CA2299271C (en) 1997-08-07 2009-02-03 University Of Utah Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof
US5847110A (en) * 1997-08-15 1998-12-08 Biomedical Frontiers, Inc. Method of reducing a schiff base
US6875594B2 (en) * 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
TR200002059T2 (tr) * 1998-01-16 2001-01-22 Takeda Chemical Industries, Ltd. Devamlı salınan bileşim, üretim yöntemi ve kullanımı.
DE19808079A1 (de) 1998-02-20 1999-08-26 Schering Ag Hydroxyethylstärke-Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US6596135B1 (en) 1998-03-05 2003-07-22 Asahi Glass Company, Limited Sputtering target, transparent conductive film, and method for producing the same
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6261594B1 (en) * 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7279176B1 (en) 1999-09-02 2007-10-09 Rice University Nitric oxide-producing hydrogel materials
US20020065410A1 (en) * 1999-12-02 2002-05-30 Antrim Richard L. Branched starches and branched starch hydrolyzates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2001294601A (ja) 2000-04-11 2001-10-23 Akita Prefecture 高度分岐澱粉と該高度分岐澱粉の製造方法
JP2002003398A (ja) 2000-04-17 2002-01-09 Ltt Institute Co Ltd 徐放製剤、その製造法及びワクチン
DE10023051B4 (de) * 2000-05-11 2004-02-19 Roche Diagnostics Gmbh Verfahren zur Herstellung von Fluoresceinisothiocyanat-Sinistrin, dessen Verwendung und Fluoresceinisothiocyanat-Sinistrin enthaltende diagnostische Zubereitung
FR2811967B1 (fr) 2000-07-24 2002-12-13 Cebal Tube muni d'une tete de fixation pour divers bouchages et les divers bouchages munis de moyens de fixation sur ledit tube
DE10041541A1 (de) 2000-08-24 2002-03-14 Michael Duchene Rekombinante Allergene aus der Motte Plodia interpunctella
US6417347B1 (en) * 2000-08-24 2002-07-09 Scimed Life Systems, Inc. High yield S-nitrosylation process
KR20030057529A (ko) 2000-09-08 2003-07-04 그리폰 테라퓨틱스, 인코포레이티드 합성 적혈구생성 자극 단백질
DE10105921A1 (de) 2001-02-09 2002-08-14 Braun Melsungen Ag An Kolloide gebundene Arzneiwirkstoffe
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10126158A1 (de) 2001-05-30 2002-12-12 Novira Chem Gmbh Eine Methode zur Synthese von Gemischen einfach aktivierter und nicht aktivierter Polyoxyalkylene zur Modifizierung von Proteinen
DE10129369C1 (de) * 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
DE10135694A1 (de) 2001-07-21 2003-02-06 Supramol Parenteral Colloids Amphiphile Stärke-und Hydroxyethylstärke-Konjugate
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
ATE469164T1 (de) 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
US6375846B1 (en) * 2001-11-01 2002-04-23 Harry Wellington Jarrett Cyanogen bromide-activation of hydroxyls on silica for high pressure affinity chromatography
DE10155098A1 (de) 2001-11-09 2003-05-22 Supramol Parenteral Colloids Mittel zur Prävention von mykotischen Kontaminationen bei der Zell- und Gewebekultur bakteriellen, pflanzlichen, animalischen und humanen Ursprungs, bestehend aus Polyen-Makrolid-Konjugaten mit Polysacchariden
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
DE10207072A1 (de) * 2002-02-20 2003-08-28 Supramol Parenteral Colloids Stärkederivate, ihre Konjugate und Verfahren zur Herstellung derselben
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
JP4272537B2 (ja) 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Ｙ型分鎖親水性ポリマー誘導体、それらの調製方法、前記誘導体および薬剤分子の結合生成物、ならびに前記結合生成物を含む医薬組成物
DE10217994A1 (de) 2002-04-23 2003-11-06 Supramol Parenteral Colloids Konjugate von hyperverzweigten Polysacchariden
EP1514107B1 (en) * 2002-06-03 2013-05-15 The Institute for Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20040101546A1 (en) 2002-11-26 2004-05-27 Gorman Anne Jessica Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
EP1591467A1 (en) 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
EP1400533A1 (en) 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
BR0314227A (pt) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
US7538092B2 (en) * 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
DE10254745A1 (de) 2002-11-23 2004-06-03 Supramol Parenteral Colloids Gmbh Imidazolide von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
DE10256558A1 (de) 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
MXPA06001358A (es) 2003-08-08 2006-05-15 Fresenius Kabi Gmbh Conjugados de hidroxialquil almidon y g-csf.
BRPI0412671A (pt) * 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
PL1660134T3 (pl) 2003-08-08 2011-05-31 Fresenius Kabi Deutschland Gmbh Koniugaty hydroksyalkiloskrobi i G-CSF
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CA2556169C (en) 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
DE102004009783A1 (de) 2004-02-28 2005-09-15 Supramol Parenteral Colloids Gmbh Hyperverzweigte Stärkefraktion, Verfahren zu ihrer Herstellung und ihre Konjugate mit pharmazeutischen Wirkstoffen
ES2390885T3 (es) * 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
WO2005092369A2 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyethyl starch and erythropoietin
US20050265958A1 (en) 2004-05-14 2005-12-01 West Jennifer L Nitric oxide releasing compositions and associated methods
CN101137396A (zh) * 2005-03-11 2008-03-05 弗雷泽纽斯卡比德国有限公司 由无活性初始材料制备生物活性糖蛋白
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AU2006309212B2 (en) 2005-10-31 2011-09-15 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
JP2009093397A (ja) 2007-10-09 2009-04-30 Panasonic Corp タッチパネル及びこれを用いた入力装置
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CA2739757C (en) 2008-10-07 2016-07-05 Rexahn Pharmaceuticals, Inc. Hpma - docetaxel or gemcitabine conjugates and uses therefore

Also Published As

Publication number Publication date
KR20050061466A (ko) 2005-06-22
TW200418875A (en) 2004-10-01
IL166506A (en) 2010-02-17
JP2010248528A (ja) 2010-11-04
EP2316850A2 (en) 2011-05-04
HK1136226A1 (en) 2010-06-25
CN1681846A (zh) 2005-10-12
US20060019877A1 (en) 2006-01-26
ES2213507T1 (es) 2004-09-01
DE60304640T2 (de) 2007-05-16
US8475765B2 (en) 2013-07-02
MXPA05002593A (es) 2005-05-27
RU2005110415A (ru) 2006-08-27
BR0314107A (pt) 2005-07-19
PL217085B1 (pl) 2014-06-30
AU2003255406B2 (en) 2009-09-10
EP2272865A3 (en) 2014-06-18
ES2213505T3 (es) 2006-11-16
IL166506A0 (en) 2006-01-15
PL374969A1 (pl) 2005-11-14
EP1398322A1 (en) 2004-03-17
EP2017287A2 (en) 2009-01-21
RU2326891C2 (ru) 2008-06-20
IL166931A (en) 2012-06-28
IL200150A0 (en) 2011-07-31
PT1398328E (pt) 2010-02-19
US20050238723A1 (en) 2005-10-27
RU2329274C2 (ru) 2008-07-20
HK1063478A1 (en) 2004-12-31
IL166930A (en) 2012-08-30
MXPA05002594A (es) 2005-05-27
CN100348618C (zh) 2007-11-14
US20110054152A1 (en) 2011-03-03
US8618266B2 (en) 2013-12-31
MX2010006175A (es) 2010-07-05
PL216545B1 (pl) 2014-04-30
KR101045401B1 (ko) 2011-06-30
ATE323723T1 (de) 2006-05-15
CA2496317C (en) 2014-02-18
BR0314106A (pt) 2005-07-19
EP2272865A2 (en) 2011-01-12
EP2017287A3 (en) 2009-11-04
AU2003260393A1 (en) 2004-04-30
AU2009238372B2 (en) 2012-08-23
ES2213506T3 (es) 2009-02-16
CY1109813T1 (el) 2014-09-10
ES2213506T1 (es) 2004-09-01
AU2003253399A1 (en) 2004-04-30
JP5455821B2 (ja) 2014-03-26
DK1398328T3 (da) 2010-03-08
CA2496317A1 (en) 2004-03-25
AU2011200219B2 (en) 2012-05-17
ATE406387T1 (de) 2008-09-15
EP1398322B1 (en) 2006-04-19
KR101174510B1 (ko) 2012-08-16
WO2004024761A1 (en) 2004-03-25
EP1681303B1 (en) 2013-09-04
ES2213507T3 (es) 2010-04-15
KR20050075336A (ko) 2005-07-20
DE03020425T1 (de) 2004-07-15
DE60304640D1 (de) 2006-05-24
WO2004024777A8 (en) 2005-03-24
NO20051427L (no) 2005-05-31
DE03020423T1 (de) 2004-07-15
RU2005110423A (ru) 2006-01-20
KR101045422B1 (ko) 2011-06-30
EP2316850A3 (en) 2011-11-09
SI1398328T1 (sl) 2010-02-26
CN1681844A (zh) 2005-10-12
ATE449112T1 (de) 2009-12-15
PL374490A1 (pl) 2005-10-31
US20100317609A1 (en) 2010-12-16
JP5275293B2 (ja) 2013-08-28
DE03020424T1 (de) 2004-07-15
EP1398327A1 (en) 2004-03-17
AU2011200219A1 (en) 2011-02-10
PL375037A1 (en) 2005-11-14
MXPA05002591A (es) 2005-09-20
ES2213505T1 (es) 2004-09-01
HK1063475A1 (en) 2004-12-31
JP2006516534A (ja) 2006-07-06
EP2154160A1 (en) 2010-02-17
RU2005110412A (ru) 2006-01-20
AU2011200158B2 (en) 2012-08-02
HK1063477A1 (en) 2004-12-31
KR20050072417A (ko) 2005-07-11
ZA200600651B (en) 2007-04-25
AU2009238372A1 (en) 2009-12-17
AU2003260393B2 (en) 2009-10-01
EP2143736B1 (en) 2012-11-07
EP1398328B1 (en) 2009-11-18
JP2011089125A (ja) 2011-05-06
US20120046240A9 (en) 2012-02-23
EP1398328A1 (en) 2004-03-17
PT1398327E (pt) 2008-10-31
DE60330098D1 (de) 2009-12-31
AU2011200158A1 (en) 2011-02-03
ES2399006T3 (es) 2013-03-25
PT1398322E (pt) 2006-08-31
AR045234A1 (es) 2005-10-19
DK1398322T3 (da) 2006-08-21
JP2010265464A (ja) 2010-11-25
US7815893B2 (en) 2010-10-19
CA2495242A1 (en) 2004-03-25
EP1681303A1 (en) 2006-07-19
RU2328505C2 (ru) 2008-07-10
AU2003253399B2 (en) 2010-10-14
US20050234230A1 (en) 2005-10-20
AU2003255406A1 (en) 2004-04-30
DK1398327T3 (da) 2008-11-10
WO2004024777A1 (en) 2004-03-25
EP2143736A1 (en) 2010-01-13
WO2004024776A1 (en) 2004-03-25
DE60323192D1 (de) 2008-10-09
AR041097A1 (es) 2005-05-04
BR0314227A (pt) 2005-10-25
DE20321836U1 (de) 2011-05-12
NO20051419L (no) 2005-05-30
EP1398327B1 (en) 2008-08-27
SI1398327T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
AR045235A1 (es) Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.
AR129907A2 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO, COMPOSICIÓN FARMACÉUTICA, PROCESO PARA LA PREPARACIÓN Y USOS
ZA200501616B (en) Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
NZ594077A (en) Process for production of delta-9-tetrahydrocannabinol
AR066773A1 (es) Proceso para preparar alcoxidos de metales alcalinos
BR0317191A (pt) Método de produção e composições aquosas curáveis por radiação
AR055993A1 (es) Proceso para producir 3-oxo-pregnano-21,17-carbolactonas, asi como 3-oxo-pregn-4-eno-21,17-carbolactonas por oxidacion del correspondiente 17-(3-hidroxipropil)-3,17-dihidroxiandrostano
WO2008052379A3 (en) Organic compounds
BRPI0506690A (pt) processo para a preparação de 1,3-butileno glicol
BRPI0506655A (pt) dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
IS7365A (is) Hvarfgjörn þynningarefni og húðir sem innihalda þau
WO2006073938A3 (en) Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
UY26133A1 (es) Derivado sustituido de pirazol.
ATE442355T1 (de) Herstellung von 4,5-dialkyl-3-acylpyrrol-2- carbonsäurederivaten durch synthese nach fischer- fink und anschliebende acylierung
HRP20080440B1 (hr) Postupak za proizvodnju spoja 5-alkoksi-4-hidroksimetilpirazola
DE602006017724D1 (de) Salicylsäurederivate
ATE259373T1 (de) Verfahren zur herstellung von flavonoiden
EA200200970A1 (ru) Способ получения циталопрама
AR029893A1 (es) Metodo para la preparacion de citalopram, intermediarios y composicion farmaceutica
NO20054088L (no) Vandig beleggingsmidler
TW200519127A (en) Method of producing hydroxyalkyl starch derivatives
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
ECSP088574A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
EP1849467A4 (en) SYNERGISTIC PHARMACEUTICAL COMPOSITION OF BAICALEIN AND BAICALIN TO TUMOR INHIBITION

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration